首页> 外文OA文献 >Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

【2h】

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

机译：1期临床试验表明，经修饰的抗MUC1嵌合抗原受体转导的T细胞可有效根除MUC1阳性转移性精囊癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Fengtao You; Licui Jiang; Bozhen Zhang; Qiang Lu; Qiao Zhou; Xiaoyang Liao; Hong Wu; Kaiqi Du; Youcai Zhu; Huimin Meng; Zhishu Gong; Yunhui Zong; Lei Huang; Man Lu; Jirong Tang; Yafen Li; Xiaochen Zhai; Xiangling Wang; Sisi Ye; Dan Chen; Lei Yuan; Lin Qi; Lin Yang;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells [J] . Fengtao You, Licui Jiang, Bozhen Zhang, Science China Life Sciences . 2016,第4期

机译：1期临床试验表明，经修饰的抗MUC1嵌合抗原受体转导的T细胞可有效根除MUC1阳性转移性精囊癌
2. Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer. [J] . Ibrahim NK, Bondarenko I, Semiglazov V, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第21期

机译：来曲唑加抗MUC1抗体AS1402在激素受体阳性的局部晚期或转移性乳腺癌中的随机II期试验。
3. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: A systematic review of phase i clinical trials [J] . XuX.-J., ZhaoH.-Z., TangY.-M. Leukemia and lymphoma . 2013,第2期

机译：使用抗CD19嵌合抗原受体转导的T细胞进行过继免疫疗法的功效和安全性：I期临床试验的系统评价
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. Generation of chimeric antigen receptor modified human T lymphocytes for the potent and dual-antigen selective eradication of human cancers in mice. [D] . Kloss, Christopher Carl. 2013

机译：嵌合抗原受体修饰的人T淋巴细胞的产生，可有效和消灭小鼠中的人类癌症。
6. A VHH-Based Anti-MUC1 Chimeric Antigen Receptor forSpecific Retargeting of Human Primary T Cells toMUC1-Positive Cancer Cells [O] . Alireza Rajabzadeh, Fatemeh Rahbarizadeh, Davoud Ahmadvand, 2021

机译：基于VHH的抗MUC1嵌合抗原受体对人原发性T细胞的特异性重新靶向muc1阳性癌细胞
7. Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer [O] . Nuhad K. Ibrahim, Kemal O. Yariz, Ihor Bondarenko, 2011

机译：Letrozole加上抗MUC1抗体As1402的随机期II试验在激素受体阳性局部晚期或转移性乳腺癌中

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

著录项

引文网络

相似文献

相关主题

期刊订阅